Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Director departure
Aprea Therapeutics, Inc. (APRE) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
08/24/2023 4 Pamukcu Rifat (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns: Converted 49,280 shares @ $0
Granted 500 shares @ $0
Converted 271,870 shares @ $0
Converted 4,928 options to buy @ $0
Converted 27,187 options to buy @ $0
Granted 2,000 options to buy @ $3.65, valued at $7.3k
08/24/2023 4 Grissinger Michael (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns: Granted 500 shares @ $0
Granted 2,000 options to buy @ $3.65, valued at $7.3k
08/24/2023 4 HENNEMAN JOHN B III (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns: Granted 500 shares @ $0
Granted 2,000 options to buy @ $3.65, valued at $7.3k
08/24/2023 4 Peters Richard (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns: Granted 500 shares @ $0
Granted 2,000 options to buy @ $3.65, valued at $7.3k
08/24/2023 4 Duey Marc (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns: Converted 4,009,690 shares @ $0
Granted 500 shares @ $0
Converted 11,610 shares @ $0
Converted 400,969 options to buy @ $0
Converted 1,161 options to buy @ $0
Granted 2,000 options to buy @ $3.65, valued at $7.3k
08/24/2023 4 Seizinger Bernd R. (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns: Granted 500 shares @ $0
Granted 2,000 options to buy @ $3.65, valued at $7.3k
08/24/2023 4 BIZZARI JEAN-PIERRE (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns: Granted 12,500 options to buy @ $3.65, valued at $45.6k
08/24/2023 3 BIZZARI JEAN-PIERRE (Director) has filed a Form 3 on Aprea Therapeutics, Inc.
08/24/2023 8-K Resignation/termination of a director
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
07/11/2023 ARS Form ARS - Annual Report to Security Holders:
07/11/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
07/05/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
06/08/2023 4 Seizinger Bernd R. (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns: Bought 4,068 shares @ $3.6294, valued at $14.8k
Bought 6,029 shares @ $3.6809, valued at $22.2k
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 4 Gruia Gabriela (Director) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns: Granted 12,500 options to buy @ $3.8999, valued at $48.7k
05/08/2023 3 Gruia Gabriela (Director) has filed a Form 3 on Aprea Therapeutics, Inc.
05/08/2023 8-K Quarterly results
04/18/2023 8-K Quarterly results
03/13/2023 4 Gilad Oren (President, CEO) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns: Converted 6,045,100 shares @ $0
Granted 4,000 shares @ $0
Converted 604,510 options to buy @ $0
Granted 16,000 options to buy @ $5.08, valued at $81.3k
03/13/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
03/03/2023 SC 13G HIRSCHMAN ORIN reports a 9.2% stake in ApreaTherapeutics, Inc.
03/01/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement"
02/27/2023 4 Hamill John P. (SrVP/CFO/Prin Fin & Acct Ofcr) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns: Granted 1,000 shares @ $5.25, valued at $5.3k
02/24/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, between Aprea Therapeutics, Inc. and Maxim Group LLC",
"Opinion of DLA Piper LLP (US)",
"Aprea Therapeutics Announces Proposed Public Offering of Common Stock DOYLESTOWN, Pa., February 22, 2023 Aprea Therapeutics, Inc. , a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response pathways, today announced it has commenced an underwritten public offering of shares of its common stock. All shares of common stock in the offering are to be sold by Aprea. In addition, Aprea intends to grant the underwriter in the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering ma...",
"Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock DOYLESTOWN, PA., February 22, 2023 Aprea Therapeutics, Inc. , a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response pathways, today announced the pricing of its previously announced underwritten public offering of 1,050,000 shares of its common stock at a public offering price of $5.25 per share. Gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $5.5 million before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Aprea has granted the underwriter a 30-day option to pu..."
02/24/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/22/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/13/2023 8-K Quarterly results
02/10/2023 8-K Quarterly results
01/30/2023 4 Hamill John P. (SrVP/CFO/Prin. Fin&Acctg. Off) has filed a Form 4 on Aprea Therapeutics, Inc.
Txns: Granted 269,879 shares @ $0
Granted 539,758 options to buy @ $0.496, valued at $267.7k
01/30/2023 3 Hamill John P. (SrVP/CFO/Prin. Fin &Acctg. Off) has filed a Form 3 on Aprea Therapeutics, Inc.
01/30/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Aprea Therapeutics Appoints John Hamill as Chief Financial Officer DOYLESTOWN, PA, January 30, 2023 – Aprea Therapeutics, Inc. , a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response pathways, today announced the appointment of John Hamill as Chief Financial Officer. Mr. Hamill joins Aprea with more than 30 years of finance and accounting experience. “Aprea Therapeutics has made substantial progress and is now reaching an exciting inflection point given the advancement of our ATR inhibitor in Phase 1 human clinical trials. I look forward to working closely with John to advance our mission of finding ways to revolutionize the treatment of cancer for patients in need of new therapies,” said Oren Gilad, Ph.D., Presi..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy